GGrantIndex
Sort

48,018 grants matching immunotherapy

Embryonic natural killer cell development and function

$579,358
Christopher Michael Sturgeon · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · HL

Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia

$579,321
Brian T Campfield · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · HL

Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia

$579,321
Brian T Campfield · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · HL

Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia

$579,321
Brian T Campfield · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · HL

Cellular & Inflammatory Pathways in Ashtma & Allergic Diseases: From IgE to Cells

$579,311
Lawrence Barry Schwartz · Virginia Commonwealth University · U19 · FY2009 · AI

Targeting the Immune System in Mouse Models of Lung Adenocarcinoma

$579,271
Katerina Abigail Politi · Yale University · R01 · FY2017 · CA

Disrupted Circadian Regulation of Cell Migration at CNS-Immune Interfaces in Aging and Alzheimer's Disease

$579,264
Laura K Fonken · University Of Texas At Austin · R01 · FY2022 · AG

Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives

$579,257
Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA

HIFU-immunotherapy in pancreatic cancer

$579,183
Katherine W Ferrara · Stanford University · R01 · FY2024 · CA

Identify the host genetic determinants of immune response and TB countrol

$579,162
Ildiko Vanrhijn · Brigham And Women'S Hospital · U19 · FY2021 · AI

TLR Immunotherapy to Eradicate Anatomic SIV Reservoirs

$579,143
James Burton Whitney · Beth Israel Deaconess Medical Center · R01 · FY2019 · AI

Improving CAR-T efficacy against solid tumors by expanding lymph node reservoirs of “stem-like” CAR-T cells

$579,054
Shivani Srivastava · Fred Hutchinson Cancer Center · R37 · FY2023 · CA

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

$579,028
Deric L Wheeler · University Of Wisconsin-Madison · R01 · FY2023 · CA

Influences of the Microenvironment on Cancer Stem Cells

$579,004
Hong Wu · University Of California Los Angeles · U01 · FY2014 · CA

Developing a translational pipeline for NF1-mutant malignancies

$578,917
Karen M Cichowski · Brigham And Women'S Hospital · U01 · FY2016 · CA

Polyamines and Hypusine in Type 1 Diabetes Pathogenesis

$578,915
Raghavendra G Mirmira · University Of Chicago · R01 · FY2025 · DK

Tumor-penetrating nano-theranostics for image-guided interventions in spontaneous feline head and neck cancer

$578,900
Yuanpei Li · University Of California At Davis · R01 · FY2021 · DE

Elucidation of Human Natural Killer Cell Development

$578,825
Aharon G Freud · Ohio State University · R01 · FY2023 · CA

Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies

$578,809
Sumithira Vasu · Ohio State University · R01 · FY2024 · CA

Delineating Functional Immunity via Image-Guided PET

$578,749
Nerissa Therese Viola · Wayne State University · R37 · FY2023 · CA

Molecular Control of Plasmacytoid Dendritic Cell Development and Function

$578,680
Boris Reizis · New York University School Of Medicine · R37 · FY2020 · AI

Escape from CAR T surveillance through lineage plasticity

$578,670
Patricia A Ernst · University Of Colorado Denver · R01 · FY2022 · CA

Endothelial-Leukocyte Adhesion in CAR T Cell Treatment Associated Neurotoxicity

$578,662
Juliane Gust · Seattle Children'S Hospital · R37 · FY2025 · CA

Testing the role of BATF as a pioneer transcription factor in effector T cells

$578,656
Cigall Kadoch · Dana-Farber Cancer Inst · R01 · FY2018 · AI

Project 2: Local immunotherapy corrects chemokine patterns in ovarian cancer

$578,652
Robert Page Edwards · Roswell Park Cancer Institute Corp · P01 · FY2020 · CA